Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of the scandinavian glioblastoma study group
Authors:
Open Access
Abstract
A prospective and randomized trial has been performed in order to evaluate combined modality therapy in patients with astrocytomas grade 3 and 4. Follow‐up information is available on 244 patients. One half of the series received radiation therapy twice a week (40.00 Gy/5 weeks), the other half five times a week (50.00 Gy/5 weeks). Misonidazole 1.2 g/m2 was given orally to one half of the patients in the first radiation treatment group 3 1/2 to 4 hours before the treatment. The other half received placebo. The second radiation treatment group was also divided in two halves, one receiving 0.48 g/m2 misonidazole and the other placebo 3 1/2 to 4 hours before radiation. The randomization also included a subdivision of the material into eight groups of which four were given CCNU and four no chemotherapy, beginning 3 months after operation. The dose of CCNU was 120 mg/m2 body surface every 6 weeks. All eight treatment groups showed practically identical periods of median survival, and no statistically significant differences were observed with regard to performance status, side effects, or complications. Another dosage and timing of misonidazole administration in relation to the irradiation schedule, and a consideration of effects of concomitant drugs like dexamethasone and phenytoin are discussed.Keywords
This publication has 14 references indexed in Scilit:
- A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus bcnu for treatment of malignant glioma after surgery; Preliminary results of an RTOG studyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1983
- A new approach to the use of misonidazole as a radiosensitizer of hypoxic tumour cellsBritish Journal of Cancer, 1982
- Malignant astrocytoma. Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trialCancer, 1982
- Post-operative radiotherapy of malignant astrocytomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1982
- Split course multiple daily fractionated radiotherapy schedule combined with misonidazole for the management of grade III and IV gliomas A pilot feasibility study of the Radiotherapy Group of the EORTCInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1982
- Final report on the united states phase i clinical trial of the hypoxic cell radiosensitizer, misonidazole (RO-07-0582; NSC #261037)Cancer, 1981
- Radiation therapy oncology group clinical trials with misonidazoleCancer, 1981
- A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytomaBritish Journal of Cancer, 1981
- Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study groupCancer, 1981
- Misonidazole and radiotherapy to treat malignant glioma: A phase II trial of the radiation therapy oncology groupInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1981